TTrialPathMatch Me to Trials
← Back to trials
RecruitingRenal Cell CarcinomaNon Small Cell Lung CancerMelanoma

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

Sponsor: Diwakar Davar

You may qualify if…

  • ✓ Able to understand and willing to sign a written informed consent document.
  • ✓ Able to read and write in English.
  • ✓ Must be eligible to receive nivolumab (Cohorts A-1, B-1) or pembrolizumab (Cohorts A-2, B-2) singly or in combination with other FDA-approved agents (TKIs or chemotherapy) according to standard of care practices, as determined by the clinical judgment of the investigator.
  • ✓ Prior and concurrent therapy criteria
  • ✓ o Patients should either be ICI-naïve (Cohorts A-1, A-2) or be currently receiving adjuvant or front-line PD-(L)1 based therapy singly or in combination with FDA-approved agents (TKIs or chemotherapy) (Cohorts B-1, B-2).
  • ✓ Locally advanced or advanced/metastatic solid tumor for which nivolumab OR pembrolizumab is on-label.
  • ✓ NOTE: IV nivolumab is FDA-approved in the following indications: RCC, melanoma, NSCLC, SCCHN, UC, dMMR/MSI-H CRC, HCC, esophageal cancer, and gastric, gastroesophageal and esophageal adenocarcinoma (gastric/GEJ).
  • ✓ NOTE: IV pembrolizumab is FDA-approved in the following indications: RCC, melanoma, NSCLC, SCCHN, UC, dMMR/MSI-H CRC, HCC, esophageal cancer, gastric/GEJ, cervical cancer, cutaneous squamous cell carcinoma (cSCC), Merkel cell carcinoma (MCC), endometrial carcinoma, tumor mutational burden-high (TMB-H) cancers, triple negative breast cancer (TNBC).

You may not qualify if…

  • ✕ Participant unable to receive nivolumab (or pembrolizumab) due to prior allergic reactions to nivolumab (or pembrolizumab) or any of its ingredients.
  • ✕ Has severe hypersensitivity (≥Grade 3) to nivolumab (or pembrolizumab) and/or any of its excipients.
  • ✕ Has had an allogenic tissue/solid organ transplant.

Where it's recruiting

Pennsylvania

Pittsburgh

Source: ClinicalTrials.gov · NCT07223424 · last updated 2026-04-16

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · TrialPath